Market Cap 70.78B
Revenue (ttm) 321.33B
Net Income (ttm) 1.55B
EPS (ttm) N/A
PE Ratio 22.80
Forward PE 20.57
Profit Margin 0.48%
Debt to Equity Ratio 4.38
Volume 1,812,400
Avg Vol 1,508,656
Day's Range N/A - N/A
Shares Out 193.88M
Stochastic %K 91%
Beta 0.63
Analysts Strong Sell
Price Target $374.64

Company Profile

Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management...

Industry: Medical Distribution
Sector: Healthcare
Phone: 610 727 7000
Address:
1 West First Avenue, Conshohocken, United States
PrivateProfiteer
PrivateProfiteer Nov. 13 at 1:08 AM
$COR is currently trading at $364.86 with a strong RSI of 83.33, indicating that it is overbought. The 30-day moving average (MA30) is at $330.02, and the 50-day moving average (MA50) is at $317.13, suggesting a bullish trend in the short to medium term. However, the high of $366.17 within the last 60 days is very close to the current price, which may limit further upside potential. Given the overbought condition indicated by the RSI and proximity to the recent high, a cautious approach is warranted. Suggested trade plan: - Entry: Consider shorting at $364.86 or a slight pullback to $362.00. - Stop: Place a stop at $368.00 to limit potential losses. - Targets: First target at $350.00 (near the MA30), second target at $340.00 (a psychological level and below MA30). Monitor price action closely for any signs of reversal. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 12 at 12:44 AM
$COR is currently trading at $364.86 with a strong RSI of 83.33, indicating that it is overbought. The 30-day moving average (MA30) is at $330.02, and the 50-day moving average (MA50) is at $317.13, suggesting a bullish trend in the short to medium term. However, the high of $366.17 within the last 60 days is very close to the current price, which may limit further upside potential. Given the overbought condition indicated by the RSI and proximity to the recent high, a cautious approach is warranted. Suggested trade plan: - Entry: Consider shorting at $364.86 or a slight pullback to $362.00. - Stop: Place a stop at $368.00 to limit potential losses. - Targets: First target at $350.00 (near the MA30), second target at $340.00 (a psychological level and below MA30). Monitor price action closely for any signs of reversal. https://privateprofiteers.com
0 · Reply
IN0V8
IN0V8 Nov. 11 at 5:01 PM
$COR JP Morgan raises target price to $417 from $344 Wells Fargo raises target price to $405 from $354
0 · Reply
JarvisFlow
JarvisFlow Nov. 11 at 3:52 PM
JP Morgan updates rating for Cencora ( $COR ) to Overweight, target set at 344 → 417.
0 · Reply
JarvisFlow
JarvisFlow Nov. 11 at 2:30 PM
Wells Fargo has updated their rating for Cencora ( $COR ) to Overweight with a price target of 405.
0 · Reply
JarvisFlow
JarvisFlow Nov. 10 at 5:28 PM
TD Cowen has adjusted their stance on Cencora ( $COR ), setting the rating to Buy with a target price of 350 → 400.
0 · Reply
IN0V8
IN0V8 Nov. 10 at 5:12 PM
$COR Opportunity TD Cowen raises target price to $400 from $350
0 · Reply
JarvisFlow
JarvisFlow Nov. 7 at 4:23 PM
UBS updates rating for Cencora ( $COR ) to Buy, target set at 380 → 415.
0 · Reply
InItToWinIt100
InItToWinIt100 Nov. 7 at 5:53 AM
$COR $IEP $MSGM On watch in the morning.
1 · Reply
InItToWinIt100
InItToWinIt100 Nov. 7 at 5:52 AM
$COR Still has room to run even more! https://www.trade-ideas.com/share.php?code=uC6RHr3dvQyQuanqjCGvLHa0SRix8aZc
0 · Reply
Latest News on COR
Cencora: Earnings Visibility Driving Re-Rating Potential

Nov 7, 2025, 2:05 PM EST - 5 days ago

Cencora: Earnings Visibility Driving Re-Rating Potential


Cencora, Inc. (COR) Q4 2025 Earnings Call Transcript

Nov 5, 2025, 4:01 PM EST - 7 days ago

Cencora, Inc. (COR) Q4 2025 Earnings Call Transcript


Cencora, Inc. (COR) Q3 2025 Earnings Call Transcript

Aug 6, 2025, 12:25 PM EDT - 3 months ago

Cencora, Inc. (COR) Q3 2025 Earnings Call Transcript


Cencora Reports Fiscal 2025 Third Quarter Results

Aug 6, 2025, 6:30 AM EDT - 3 months ago

Cencora Reports Fiscal 2025 Third Quarter Results


Cencora Elects Lori J. Ryerkerk to Its Board of Directors

May 28, 2025, 7:30 AM EDT - 6 months ago

Cencora Elects Lori J. Ryerkerk to Its Board of Directors


Cencora, Inc. (COR) Q2 2025 Earnings Call Transcript

May 7, 2025, 10:55 AM EDT - 6 months ago

Cencora, Inc. (COR) Q2 2025 Earnings Call Transcript


Cencora Reports Fiscal 2025 Second Quarter Results

May 7, 2025, 6:30 AM EDT - 6 months ago

Cencora Reports Fiscal 2025 Second Quarter Results


3 Nearly Trump-Proof Stocks Defying Trump's Tariff Shock

Apr 4, 2025, 3:42 PM EDT - 7 months ago

3 Nearly Trump-Proof Stocks Defying Trump's Tariff Shock

CVS MCK PM


Cencora: Higher Potential Returns After Reduced Walgreens Stake

Feb 26, 2025, 11:00 AM EST - 9 months ago

Cencora: Higher Potential Returns After Reduced Walgreens Stake


Cencora (COR) Q1 2025 Earnings Call Transcript

Feb 5, 2025, 11:40 AM EST - 10 months ago

Cencora (COR) Q1 2025 Earnings Call Transcript


Cencora raises 2025 profit forecast on specialty drug demand

Feb 5, 2025, 7:23 AM EST - 10 months ago

Cencora raises 2025 profit forecast on specialty drug demand


Cencora Reports Fiscal 2025 First Quarter Results

Feb 5, 2025, 6:30 AM EST - 10 months ago

Cencora Reports Fiscal 2025 First Quarter Results


Cencora raises annual profit forecast

Jan 2, 2025, 4:23 PM EST - 11 months ago

Cencora raises annual profit forecast


Cencora Completes Acquisition of Retina Consultants of America

Jan 2, 2025, 4:15 PM EST - 11 months ago

Cencora Completes Acquisition of Retina Consultants of America


Cencora Closes $1.8 Billion Senior Notes Offering

Dec 9, 2024, 4:15 PM EST - 1 year ago

Cencora Closes $1.8 Billion Senior Notes Offering


Cencora: Competitive Advantages Defined

Dec 5, 2024, 10:26 AM EST - 1 year ago

Cencora: Competitive Advantages Defined


Cencora to Host Inaugural Product Showcase

Nov 26, 2024, 8:30 AM EST - 1 year ago

Cencora to Host Inaugural Product Showcase


Cencora, Inc. (COR) Q4 2024 Earnings Call Transcript

Nov 6, 2024, 10:56 AM EST - 1 year ago

Cencora, Inc. (COR) Q4 2024 Earnings Call Transcript


Cencora to buy Retina Consultants of America for $4.6 bln

Nov 6, 2024, 6:54 AM EST - 1 year ago

Cencora to buy Retina Consultants of America for $4.6 bln


PrivateProfiteer
PrivateProfiteer Nov. 13 at 1:08 AM
$COR is currently trading at $364.86 with a strong RSI of 83.33, indicating that it is overbought. The 30-day moving average (MA30) is at $330.02, and the 50-day moving average (MA50) is at $317.13, suggesting a bullish trend in the short to medium term. However, the high of $366.17 within the last 60 days is very close to the current price, which may limit further upside potential. Given the overbought condition indicated by the RSI and proximity to the recent high, a cautious approach is warranted. Suggested trade plan: - Entry: Consider shorting at $364.86 or a slight pullback to $362.00. - Stop: Place a stop at $368.00 to limit potential losses. - Targets: First target at $350.00 (near the MA30), second target at $340.00 (a psychological level and below MA30). Monitor price action closely for any signs of reversal. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 12 at 12:44 AM
$COR is currently trading at $364.86 with a strong RSI of 83.33, indicating that it is overbought. The 30-day moving average (MA30) is at $330.02, and the 50-day moving average (MA50) is at $317.13, suggesting a bullish trend in the short to medium term. However, the high of $366.17 within the last 60 days is very close to the current price, which may limit further upside potential. Given the overbought condition indicated by the RSI and proximity to the recent high, a cautious approach is warranted. Suggested trade plan: - Entry: Consider shorting at $364.86 or a slight pullback to $362.00. - Stop: Place a stop at $368.00 to limit potential losses. - Targets: First target at $350.00 (near the MA30), second target at $340.00 (a psychological level and below MA30). Monitor price action closely for any signs of reversal. https://privateprofiteers.com
0 · Reply
IN0V8
IN0V8 Nov. 11 at 5:01 PM
$COR JP Morgan raises target price to $417 from $344 Wells Fargo raises target price to $405 from $354
0 · Reply
JarvisFlow
JarvisFlow Nov. 11 at 3:52 PM
JP Morgan updates rating for Cencora ( $COR ) to Overweight, target set at 344 → 417.
0 · Reply
JarvisFlow
JarvisFlow Nov. 11 at 2:30 PM
Wells Fargo has updated their rating for Cencora ( $COR ) to Overweight with a price target of 405.
0 · Reply
JarvisFlow
JarvisFlow Nov. 10 at 5:28 PM
TD Cowen has adjusted their stance on Cencora ( $COR ), setting the rating to Buy with a target price of 350 → 400.
0 · Reply
IN0V8
IN0V8 Nov. 10 at 5:12 PM
$COR Opportunity TD Cowen raises target price to $400 from $350
0 · Reply
JarvisFlow
JarvisFlow Nov. 7 at 4:23 PM
UBS updates rating for Cencora ( $COR ) to Buy, target set at 380 → 415.
0 · Reply
InItToWinIt100
InItToWinIt100 Nov. 7 at 5:53 AM
$COR $IEP $MSGM On watch in the morning.
1 · Reply
InItToWinIt100
InItToWinIt100 Nov. 7 at 5:52 AM
$COR Still has room to run even more! https://www.trade-ideas.com/share.php?code=uC6RHr3dvQyQuanqjCGvLHa0SRix8aZc
0 · Reply
JarvisFlow
JarvisFlow Nov. 6 at 5:34 PM
Baird updates rating for Cencora ( $COR ) to Outperform, target set at 355 → 395.
0 · Reply
IN0V8
IN0V8 Nov. 6 at 3:18 PM
$COR Opportunity Baird raises target price to $395 from $355 Leerink Partners raises target price to $410 from $361
0 · Reply
JarvisFlow
JarvisFlow Nov. 6 at 1:00 PM
Mizuho has updated their rating for Cencora ( $COR ) to Outperform with a price target of 380.
0 · Reply
PanicSeller8
PanicSeller8 Nov. 5 at 9:50 PM
$MCK $COR $CAH Criminally under appreciated.
1 · Reply
oracle11
oracle11 Nov. 5 at 8:26 PM
$COR GREAT stock
0 · Reply
Lol_at_ur_bags
Lol_at_ur_bags Nov. 5 at 8:11 PM
$APP $AXON $COR $SEDG Nobody reads your post, that’s why you have like 7+ banned accounts. You bought your 9.2k followers yet never have any likes or engagement. Sybau bot
0 · Reply
cubie
cubie Nov. 5 at 8:07 PM
$APP They didnt play both ways on $AXON $COR $SEDG !! Wtf, u read zero of my posts yesterday smh
1 · Reply
prismmarketview
prismmarketview Nov. 5 at 8:06 PM
(NYSE: $COR) Cencora will invest $1.X billion through 2030 to expand and modernize its U.S. pharmaceutical distribution network, opening a second national distribution center in Ohio by spring 2027, expanding facilities in California and Alabama, and enhancing capacity, efficiency, and resilience to meet growing demand for specialty medicines. https://prismmarketview.com/cencora-commits-1-billion-to-strengthen-u-s-pharmaceutical-distribution-network/
0 · Reply
cubie
cubie Nov. 5 at 3:39 PM
$COR $CAH $MCK Congrats smart peeps who played after😑
0 · Reply
StocktwitsNews
StocktwitsNews Nov. 5 at 12:40 PM
Cencora Announces $1B Investment In US $COR $DUHP $VFMF https://stocktwits.com/news/equity/markets/cencora-announces-one-billion-investment-in-us/cL2qSFcREGZ
0 · Reply
ZacksResearch
ZacksResearch Nov. 5 at 6:00 AM
$COR earnings beat streak — will it continue? 📊 👀 Q4 revenue projected at $83.16B, EPS expected to grow 13.5% from the prior-year quarter. 🤔 Positive Earnings ESP of +0.31% and Zacks Rank #3 suggest a likely beat. Discover what factors might impact COR's results this quarter 👉 https://www.zacks.com/stock/news/2783253/can-specialty-and-glp-1-momentum-support-cencoras-q4-results?cid=sm-stocktwits-2-2783253-body-18996&ADID=SYND_STOCKTWITS_TWEET_2_2783253_BODY_18996
0 · Reply
cubie
cubie Nov. 4 at 8:23 PM
$COR @judgeyoung2 interesting, opposite of $SEDG and $AXON 😅
1 · Reply